A Moment of Grace for Cystic Fibrosis Patients in Lebanon

It was precisely on April 23, coinciding with the National Day of Cystic Fibrosis, when Vall D'Hebron Hospital gave the official exit gun to its clinical trial treating the first patient in Spain and fourth in the world with DNA correction therapy. A treatment that aims to introduce into the nucleus of the cell a functional copy of the CFTR gene to restore its activity and thus reduce the impact of this chronic and hereditary disease, most commo…

The Spanish Society of Pneumology and Thoracic Surgery (SEPAR) has welcomed the recent recommendation of the European Medical Agency (EMA) to extend the therapeutic indication of the medicinal products 'Kalydeco' (ivacaftor) and 'Kaftrio' (ivacaftor/tezacaftor/elexacaftor ) to treat cystic fibrosis, and to include its use in combination in patients aged two years or more who have at least one non-class I mutation in the transmembrane behavioural…

A Moment of Grace for Cystic Fibrosis Patients in Lebanon

Editor’s note: This article was originally published by Anera here. In Lebanon, access to medication for common chronic illnesses has been fraught with uncertainty in recent years. Access to medications for rare diseases like cystic fibrosis is even more limited. Treatment options are limited and prohibitively expensive. Many patients confront both financial and logistical barriers to secure the life-saving medication they need. For Gabriella, a…